Menkes Disease Market

Market Overview:

The 7 major Menkes disease markets are expected to exhibit a CAGR of 5.88% during 2024-2034.

The Menkes disease market has been comprehensively analyzed in IMARC's new report titled "Menkes Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Menkes disease refers to a rare genetic disorder that affects the body's ability to absorb and utilize copper. This condition is caused by mutations in the ATP7A gene, which provides instructions for making a protein that transports copper within the body. Menkes disease is generally characterized by an unstable body temperature, along with strikingly tangled hair that is steel-colored or colorless, sparse, and prone to breaking. The symptoms of the ailment typically begin in infancy and may include weak muscle tone, seizures, failure to thrive, intellectual disability, etc. Individuals suffering from Menkes disease have significantly reduced levels of copper in the brain and liver, which can cause severe neurological and developmental problems. The initial step in diagnosing this ailment includes a review of the patient's medical history, symptoms, and physical examination. A plasma catecholamine analysis is also recommended to measure certain natural neurochemicals in patients. The healthcare provider may further perform blood and genetic testing for the evaluation of abnormal changes in the body.

The increasing cases of X-linked genetic disorders resulting from a non-working gene on the X chromosome are primarily driving the Menkes disease market. In addition to this, the widespread adoption of pain relievers and anti-seizure drugs to help reduce disease symptoms in patients is also bolstering the market growth. Furthermore, the inflating demand for copper histidinate (CuHis) treatment, since it can stabilize copper, improve neurological development, and lower the occurrence of epilepsy, is acting as another significant growth-inducing factor. Apart from this, the escalating utilization of physical and occupational therapy for enhancing functional efficiency in patients is also creating a positive outlook for the market. Moreover, numerous key players are making substantial investments in research activities for the launch of novel therapies that are easily accessible and cost-effective. This, in turn, is further propelling the market growth. Additionally, the emerging popularity of gene therapy, in which a harmless virus containing the normal gene is utilized to replace the faulty gene with a healthy one to prevent or treat the ailment, is expected to drive the Menkes disease market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Menkes disease market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Menkes disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Menkes disease market in any manner.

Recent Developments:

• In December 2023, Sentynl Therapeutics, Inc. (Sentynl) announced the signing of an Assignment and Assumption Agreement with Cyprium Therapeutics, Inc. Cyprium transferred its worldwide proprietary rights and U.S. FDA paperwork for CUTX-101, a copper histidinate product candidate for the treatment of Menkes disease, to Sentynl under the terms of the agreement.

Key Highlights:

• Menkes disease affects around 1 out of every 35,000 live male newborns.
• The condition is X-linked and consequently mostly affects men.
• Females are often carriers, though cases have been observed due to rare genetic circumstances.
• In the United States, the incidence ranges between 1 in 50,000 and 1 in 250,000, with one-third of these instances caused by novel mutations.
• The incidence in Australia is substantially greater (1 in 50,000 to 1 in 1,000,000), which could be attributed to the founder effect.

Drugs:

CUTX-101 is being developed clinically to treat Menkes disease. CUTX-101 is a subcutaneous injectable formulation of Copper Histidinate made using current good manufacturing practice (cGMP) and physiological pH.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Menkes disease market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Menkes disease market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Menkes disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Menkes disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the Menkes disease market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the Menkes disease market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of Menkes disease across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of Menkes disease by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of Menkes disease by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with Menkes disease across the seven major markets?
• What is the size of the Menkes disease patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of Menkes disease?
• What will be the growth rate of patients across the seven major markets?
   

Menkes Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Menkes disease drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Menkes disease market?
• What are the key regulatory events related to the Menkes disease market?
• What is the structure of clinical trial landscape by status related to the Menkes disease market?
• What is the structure of clinical trial landscape by phase related to the Menkes disease market?
• What is the structure of clinical trial landscape by route of administration related to the Menkes disease market?